Business Context and Reporting Period
This Form 8-K is a current report filed by Predictive Oncology Inc. (not Axe Compute Inc.) on June 2, 2025. The filing addresses an update to the company's "at-the-market" (ATM) equity offering program. The company is incorporated in Delaware and trades on the NASDAQ Capital Market under the symbol POAI.
Key Financial Metrics and Capital Structure
The filing does not report standard operating metrics such as revenue, profit, cash flow, or margins. It focuses exclusively on capital raising capacity under the ATM program:
- ATM Sales Limit: As of June 2, 2025, the company is eligible to sell common stock with an aggregate offering price of up to $3,398,000.
- Amount Sold to Date: Approximately $684,467 of securities have been sold pursuant to General Instruction I.B.6 of Form S-3.
- Public Float Threshold: The company notes that if its public float increases above $75.0 million, it will no longer be subject to the specific limits of General Instruction I.B.6 of Form S-3.
Material Changes
The primary material change is the amendment of the prospectus supplement dated April 18, 2025. This update specifies the maximum value of common stock the company is permitted to sell in any 12-calendar-month period under the ATM Sales Agreement with H.C. Wainwright & Co., LLC. The filing clarifies that the company will file additional supplements if its public float increases, allowing for the sale of additional amounts.
Guidance, Outlook, and Risks
Management Commentary: The filing states that the company will file another prospectus supplement prior to making additional sales if its public float increases sufficiently to allow for higher sales volumes under the agreement.
Risks and Contingencies: The filing includes a standard disclaimer that the report does not constitute an offer to sell or a solicitation of an offer to buy securities in any jurisdiction where such an offer would be unlawful prior to registration or qualification.
Investor Verification Checklist
- Verify the discrepancy between the requested company name ("Axe Compute Inc.") and the actual registrant ("Predictive Oncology Inc.") in the source text.
- Confirm the current public float of Predictive Oncology Inc. to assess if the $75.0 million threshold for increased ATM capacity has been met.
- Review the original ATM Sales Agreement dated May 3, 2024, to understand the full terms of the engagement with H.C. Wainwright & Co., LLC.
- Monitor future filings for additional prospectus supplements if the company's public float increases.